I don't think the parent was taking much issue with the blog posts or the fact that he's a tutor. I think it's his previous companies, plus this paragraph from the post:
> So, first of all, the confession: I’m not a neutral observer here. In talking about this paper, I’m talking my own book. My company, Highway Pharmaceuticals, is currently raising funds to get a safer, easier to use, extended-release version of cyclosporine, the most common calcineurin inhibitor, into first-in-human trials. If this paper is correct, investors should probably consider throwing money at me.
Yes, this. I enjoyed the blog post. It was an easy read, the idea is intriguing, it linked to a related paper. I found the plug for the company mildly offputting, and decided to see if the author was someone actively working in this space.
I don't think anyone needs credentials to have an interesting idea, but it's laughable that someone with no lab or research or business experience is an actual player in this space. I guess people can invest in him if they want. The idea that he's fundraising for human trials is laughable.
> So, first of all, the confession: I’m not a neutral observer here. In talking about this paper, I’m talking my own book. My company, Highway Pharmaceuticals, is currently raising funds to get a safer, easier to use, extended-release version of cyclosporine, the most common calcineurin inhibitor, into first-in-human trials. If this paper is correct, investors should probably consider throwing money at me.